These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 26055804)
1. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. Benninger F; Khlebtovsky A; Roditi Y; Keret O; Steiner I; Melamed E; Djaldetti R Gait Posture; 2015 Sep; 42(3):263-8. PubMed ID: 26055804 [TBL] [Abstract][Full Text] [Related]
2. Can postural abnormality really respond to levodopa in Parkinson's disease? Kataoka H; Ueno S J Neurol Sci; 2017 Jun; 377():179-184. PubMed ID: 28477691 [TBL] [Abstract][Full Text] [Related]
3. The effect of Parkinson's disease and levodopa on adaptation of anticipatory postural adjustments. Hall LM; Brauer SG; Horak F; Hodges PW Neuroscience; 2013 Oct; 250():483-92. PubMed ID: 23867768 [TBL] [Abstract][Full Text] [Related]
4. Levodopa effect upon functional balance of Parkinson's disease patients. Nova IC; Perracini MR; Ferraz HB Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397 [TBL] [Abstract][Full Text] [Related]
5. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease. Chen H; Fang J; Li F; Gao L; Feng T Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444 [TBL] [Abstract][Full Text] [Related]
6. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465 [TBL] [Abstract][Full Text] [Related]
7. Prosody and levodopa in Parkinson's disease. Azevedo LL; Reis CA; Souza IS; Cardoso FE Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867 [TBL] [Abstract][Full Text] [Related]
8. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076 [TBL] [Abstract][Full Text] [Related]
9. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
10. Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease. Benice TS; Lou JS; Eaton R; Nutt J Clin Neurophysiol; 2007 Aug; 118(8):1776-84. PubMed ID: 17576094 [TBL] [Abstract][Full Text] [Related]
11. Axial hypertonicity in Parkinson's disease: direct measurements of trunk and hip torque. Wright WG; Gurfinkel VS; Nutt J; Horak FB; Cordo PJ Exp Neurol; 2007 Nov; 208(1):38-46. PubMed ID: 17692315 [TBL] [Abstract][Full Text] [Related]
12. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Fahn S; J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436 [TBL] [Abstract][Full Text] [Related]
14. Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease. Defebvre LJ; Krystkowiak P; Blatt JL; Duhamel A; Bourriez JL; Périna M; Blond S; Guieu JD; Destée A Mov Disord; 2002 Jan; 17(1):76-83. PubMed ID: 11835442 [TBL] [Abstract][Full Text] [Related]
15. Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease. Umemura A; Oka Y; Ohkita K; Yamawaki T; Yamada K J Neurosurg; 2010 Jun; 112(6):1283-8. PubMed ID: 19895200 [TBL] [Abstract][Full Text] [Related]
16. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
17. [Early treatment of Parkinson's disease with levodopa]. Odekerken VJ; Post B; Verschuur CV; de Bie RM Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]